Earnings ·
CytoMed Therapeutics reports S$1.79M net loss, down 20.1% from prior year
GDTCCytoMed Therapeutics Ltd
CytoMed Therapeutics Limited filed its Unaudited Interim Condensed Consolidated Financial Statements for the six months ended June 30, 2026. The company reported a net loss of S$1.79 million (US$1.39 million), a 20.1% decrease from the S$2.25 million loss in the same period last year. Revenue from private blood banking services increased marginally to S$157,289, while other operating income declined to S$254,719 due to lower interest and research income. Cash balances decreased to S$1.46 million as net cash used in operations totaled S$1.65 million. Financing activities generated S$963,664, primarily from a S$699,600 loan from a director and S$300,000 from non-controlling interest share issuance. The company also disclosed an ATM sales agreement allowing up to US$4.30 million in equity sales, with US$237,550 raised to date. CytoMed Therapeutics Limited operates as a clinical-stage biopharmaceutical company developing allogeneic cell-based immunotherapies for cancers and degenerative diseases.